Mateusz Olbromski

Dr. Mateusz Olbromski

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2013 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
Bartosz PulaBartosz Pula
Bartosz Pula
MOMateusz Olbromski
Mateusz Olbromski
AWAndrzej Wojnar
Andrzej Wojnar
AGAgnieszka Gomulkiewicz
Agnieszka Gomulkiewicz
WWWojciech Witkiewicz
Wojciech Witkiewicz
MPMarzena Podhorska-Okolow
Marzena Podhorska-Okolow

7 October 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
AJAleksandra Jethon
Aleksandra Jethon
Bartosz PulaBartosz Pula
Bartosz Pula
MOMateusz Olbromski
Mateusz Olbromski
BWBozena Werynska
Bozena Werynska
BMBeata Muszczynska-Bernhard
Beata Muszczynska-Bernhard
MPMarzena Podhorska-Okolow
Marzena Podhorska-Okolow
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

1 July 2015
Verified
Journal Article
Closed access
JGJedrzej Grzegrzolka
Jedrzej Grzegrzolka
MBMartyna Biala
Martyna Biala
PWPatrycja Wojtyra
Patrycja Wojtyra
CKChristopher Kobierzycki
Christopher Kobierzycki
MOMateusz Olbromski
Mateusz Olbromski
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel

1 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAlicja Kmiecik
Alicja Kmiecik
Bartosz PulaBartosz Pula
Bartosz Pula
JSJaroslaw Suchanski
Jaroslaw Suchanski
MOMateusz Olbromski
Mateusz Olbromski
AGAgnieszka Gomulkiewicz
Agnieszka Gomulkiewicz
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
It has been recently found that metallothionein-3 (MT3) enhances the invasiveness and tumorigenesis of prostate cancer cells. This finding is in contrast to those of earlier studies, which indicated that overexpression of MT3 in breast cancer and prostate cancer cell lines inhibits their growth in vitro. Therefore, to clarify the role of MT3 in breast cancer progression, we analyzed the effect of MT3-overexpression on proliferation, invasiveness, migration, and tumorigenesis of breast cancer MDA-MB-231/BO2 cells. It was found that MDA-MB-231/BO2 cells overexpressing MT3 were characterized by increased invasiveness in vitro, compared to the control cells. Interestingly, this increased invasiveness correlated with a highly increased concentration of MMP3 in the culture supernatants (p<0.0001). Our data suggest that MT3 may regulate breast cancer cell invasiveness by modulating the expression of MMP3. These experimental results, obtained using triple-negative MDA-MB-231/BO2 cells, were further supported by clinical data. It was found that, in triple-negative breast cancer (TNBC), nuclear MT3 immunoreactivity in cancer cells tended to be associated with patients’ shorter disease-specific survival, suggesting that nuclear MT3 expression may be a potential marker of poor prognosis of triple-negative TNBC cases.

13 March 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Agnieszka RusakAgnieszka Rusak
Agnieszka Rusak
Igor BuzalewiczIgor Buzalewicz
Igor Buzalewicz
MMMonika Mrozowska
Monika Mrozowska
Benita WiatrakBenita Wiatrak
Benita Wiatrak
KHKatarzyna Haczkiewicz-Leśniak
Katarzyna Haczkiewicz-Leśniak
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Glioblastoma is one of the most aggressive tumours with a poor response to treatment and a poor prognosis for patients. One of the proteins expressed in glioblastoma tissue is CHI3L1 (YKL-40), which is upregulated and known for its angiogenesis-supporting and pro-tumour immunomodulatory effects in a variety of cancers. In this paper we present the anti-angiogenic, anti-migratory and immunomodulatory effects of the compound G721-0282, an inhibitor of CHI3L1. The inhibitor-induced changes were investigated using conventional techniques as well as the novel label-free digital holographic tomography (DHT), a quantitative phase imaging technique that allows the reconstruction of the refractive index (RI), which is used as an image contrast for 3D visualisation of living cells. DHT allowed digital staining of individual cells and intercellular structures based only on their specific RI. Quantitative spatially resolved analysis of the RI data shows that the concentration of G721-0282 leads to significant changes in the density of cells and their intracellular structures (in particular the cytoplasm and nucleus), in the volume of lipid droplets and in protein concentrations. Studies in the U-87 MG glioblastoma cell line, THP-1 monocytes differentiated into macrophages, human microvascular endothelial cells (HMEC-1) and in the spheroid model of glioblastoma composed of U-87 MG, HMEC-1 and macrophages suggest that inhibition of CHI3L1 may have potential in the antitumour treatment of glioblastoma. In this paper, we also propose a spheroid model for in vitro studies that mimics this type of tumour.

25 May 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MOMateusz Olbromski
Mateusz Olbromski
MPMarzenna Podhorska‑Okołów
Marzenna Podhorska‑Okołów
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
There is a high demand for anticancer drugs due to the fact that the chemotherapeutics currently used have numerous side effects, which lowers the patient's quality of life. However, the latest antibody therapies are extremely expensive, hence the requirement to identify novel, equally effective but low‑toxic treatments that have limited side effects. As a result of this, a number of research centres around the world are attempting to identify novel molecular markers that could be effective targets for anticancer therapy in the future. The SOX18 protein has been suggested to be a significant diagnostic and prognostic marker in various types of cancer. SRY‑related HMG‑box 18 (SOX18) is an important transcription factor involved in the development of cardiovascular and lymphatic vessels during embryonic development. In addition, it is involved in the progression of atherosclerosis and wound‑healing processes. It has been observed that its level is higher in a number of cancer types, including melanoma, pancreas, stomach, liver, breast, lung, ovarian and cervical cancer. Furthermore, an association between a high expression of SOX18 in gastric cancer stromal cells and a poor prognosis has been demonstrated. The literature indicates how complex the pathogenesis of cancer is. Knowing the molecular basis of the pathogenesis of the tumor will allow for the effective use of targeted therapy, which may result in a higher success in treating patients. It is therefore important to identify novel and effective therapies as well as new proteins that could be potential markers. The SOX18 family, represented by the SOX18 protein, seems to be in this respect a promising element in modern anticancer therapy.